An Early Phase 1 interventional study of pentoxifylline and Vit E in Infertility, Female, sponsored by Benha University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-26.
Sponsored by Benha University · Early Phase 1, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Infertility, Female with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Infertility, Female · Egypt.
Among the 60 studies in Infertility, Female with a site in Egypt, this one is the 24th largest by planned enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2018, is one of 2 in phase 1, and was the 15th registered.
553 studies on the registry are indexed under Infertility, Female; 134 are open to participants now.
Browse Infertility, Female studies →6 of the 60 studies in Infertility, Female with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 18–43 · Women only
Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy · Sites in Egypt
Ages 20–40 · Women only
Assiut University · Sites in Egypt
Ages 18–40 · Women only
Assiut University · Sites in Egypt
Ages 18–35 · Women only
Zagazig University · Sites in Egypt
Ages 21–40 · Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 89 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 78 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 39 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 6 · Phase 4 15
First in 2013; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 141 across the 46 interventional studies, 163 across the 14 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 60 have an industry lead sponsor. The 10 most frequent:
Benha University is the lead sponsor of 364 studies on the registry; 67 are open to participants now.
Benha University has 2 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Infertility, Female with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Our findings will provide preliminary clinical evidence to suggest the new experimental treatment approaches, toward female factor infertility treatment with pentoxyfylline.
This randomized clinical trial will be conducted on 140 infertile patients. The study is approved by the Ethical Committee of Benha obstetrics and Gynecology Department and will be initiated after achieving written consents of the participants. The study will include infertile patients under 39 years of age without a previous history of ICSI cycle. Exclusion criteria will be hypothalamic amenorrhea, drug reactions or complications, endometriosis and fibroids. Patients will be randomly divided into two equal groups. Computer generated random number table will be used for randomization. Group assignments will be placed in sealed opaque sequentially numbered envelopes. For each participant a questionnaire will be filled by the researchers. The questionnaire contained questions about age, duration of infertility, the type and cause of infertility. Data will be collected from questionnaires, clinical, laboratory notes and ultrasound reports. Endometrial thickness will be measured on the day of the HCG prescription in both groups by one of the two attending physicians. Chemical pregnancy will be detected by serum beta-hCG analysis 14 days after embryo transfer and transvaginal ultrasound scan will be scheduled 2 weeks later to confirm the diagnosis of clinical pregnancy. The intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
Sample size calculation Sample size was calculated using PASS® version 11 program, setting the type-1 error (α) at 0.05 and the power (1-β) at 0.8. Results from a previous study (Ashraf alesyan, 2009) showed that the incidence of pregnancy rate among ttt group was 57.1% while for control group it was 39.2%, with an effect size of 12%. Calculation according to these values produced a minimal sample size of 131 cases in each group.
Results
Results will be statistically analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
Drug: pentoxifylline · Drug: Vit E
. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
Also known as: Trental S.R. 400 mg/BD
will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
Also known as: Vit E PHARCO 400 mg/BD
clinical pregnancy rate.
serum beta-hCG analysis 14 days after embryo transfer
Time frame: two weeks after embryo transfer
clinical pregnancy rate
transvaginal ultrasound scan will be scheduled 2 weeks after embryo transfer to confirm the diagnosis of clinical pregnancy
Time frame: two weeks after embryo transfer
Start is estimated for May 2018; primary completion for Sep 2018, 4 months later.
Of 15 phase 1 interventional studies under Infertility, Female, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pentoxifylline